id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2001-D-0219-0014,FDA,FDA-2001-D-0219,"Tab E - Tab E-Guidance for Industry, ICR E6, Good Clinica1 Practice: Consolidated Guidance, April 1996 [Guidance of 3/28/2006]",Supporting & Related Material,BKG-Background Material,2010-05-10T04:00:00Z,2010,5,,,2010-05-10T20:08:54Z,,0,0,09000064804e4eb3
FDA-2001-D-0219-0013,FDA,FDA-2001-D-0219,"Tab D - Guidance for Industry, ICH E9, Statistical Principles forClinical Trials, September 1998 [Guidance of 3/28/2006]",Supporting & Related Material,BKG-Background Material,2010-05-10T04:00:00Z,2010,5,,,2010-05-10T20:08:52Z,,0,0,09000064804e4eac
FDA-2001-D-0219-0010,FDA,FDA-2001-D-0219,"Clinical Trial Sponsors on the Establishment & Operation of Clinical Trial Monitoring Committees, November 2201 - Draft Guidance",Supporting & Related Material,GDL-Guidance,2010-05-10T04:00:00Z,2010,5,,,2010-05-10T18:54:00Z,,0,0,09000064804e4dee
FDA-2001-D-0219-0011,FDA,FDA-2001-D-0219,List of References [Guidance for Clinical Trial SponsorsEstablishment & Operation of Clinical Trial Monitoring Committees 3/28/2006],Supporting & Related Material,BKG-Background Material,2010-05-10T04:00:00Z,2010,5,,,2010-05-10T19:48:22Z,,0,0,09000064804e4ea1
FDA-2001-D-0219-0012,FDA,FDA-2001-D-0219,"Tab C - DHHS, Finaneial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection May 5, 2004. [Guidance of 3/28/2006]",Supporting & Related Material,BKG-Background Material,2010-05-10T04:00:00Z,2010,5,,,2010-05-10T19:45:19Z,,0,0,09000064804e4ea3